VIDEO: Terns Pharma ‘builds upon pipeline’ of NASH, obesity research
Click Here to Manage Email Alerts
In a Healio video exclusive, Diana Chung, chief development officer at Terns Pharmaceuticals, highlights data on TERN-501, a thyroid hormone receptor beta-agonist for patients with nonalcoholic steatohepatitis.
At the 2022 International Liver Congress, Terns conducted five oral and poster presentations on data from three programs, including TERN-501, which recently was evaluated in the company’s first-in-human study. Results showed TERN-501 was safe and well-tolerated in patients across all doses, Chung reported.
“We were very excited to be able to present this data at EASL, and it was quite timely in the sense that we are in the process of initiating our phase 2a DUET study evaluating 140 patients with presumed NASH. ... We are poised to have this data available in the second half of 2023,” Chung said. “We're very excited to continue the momentum of our clinical development programs as well as being able to build upon our pipeline not only in NASH but also in obesity and cancer.”
Reference:
- Kowdley KV, et al. Poster SAT107. Presented at: International Liver Congress; June 22-26, 2022; London (hybrid meeting).
- Lawitz E, et al. Poster SAT106. Presented at: International Liver Congress; June 22-26, 2022; London (hybrid meeting).
- Nelson CH, et al. Abstract OS123. Presented at: International Liver Congress; June 22-26, 2022; London (hybrid meeting).
- Nelson CH, et al. Poster SAT108. Presented at: International Liver Congress; June 22-26, 2022; London (hybrid meeting).
- Noureddin M, et al. Poster SAT142. Presented at: International Liver Congress; June 22-26, 2022; London (hybrid meeting).
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts